Alentis Therapeutics Company
Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.
Investors
.png)
Headquarters:
Allschwil, Basel-Landschaft, Switzerland, Europe
Founded Date:
2019-01-01
Industry:
Drug Discovery & Development
Employee Number:
51-100
Super Industry:
Biopharma & Life Science Tools
Investors:
Bpifrance, Catalio Capital Management, HTGF (High-Tech Gruenderfonds), RA Capital Management, Schroders Capital
Ipo Status:
private
City:
Allschwil
Region:
Basel-Landschaft
Country:
Switzerland
Founders:
Neil Goldsmith, Thomas Baumert